Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Operations (Tables)

v3.19.2
Organization and Nature of Operations (Tables)
6 Months Ended
Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of company's subsidiaries consolidated financial statements
Name of Subsidiaries   Place and date of Incorporation   Percentage of Ownership   Principal Activities

Avalon Healthcare System, Inc.

("AHS")

 

 

Delaware

May 18, 2015

 

 

100% held by AVCO

 

  Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America ("USA")
             

Avalon (BVI) Ltd.

("Avalon BVI")

 

British Virgin Island

January 23, 2017

  100% held by AVCO  

Dormant,

is in process of being dissolved

             

Avalon RT 9 Properties LLC

("Avalon RT 9")

 

 

New Jersey

February 7, 2017

 

 

100% held by AVCO

 

  Owns and operates an income-producing real property and holds and manages the corporate headquarters
             

Avalon (Shanghai) Healthcare Technology Co., Ltd.

("Avalon Shanghai")

 

PRC

April 29, 2016

  100% held by AHS   Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in China
             

GenExosome Technologies Inc.

("GenExosome")

 

Nevada

July 31, 2017

  60% held by AVCO   Develops proprietary diagnostic and therapeutic products leveraging exosome technology and markets
             

Beijing Jieteng (GenExosome) Biotech Co., Ltd.

("Beijing GenExosome")

 

PRC

August 7, 2015

  100% held by GenExosome   Provides development services for hospitals and other customers and sells developed items to hospitals and other customers in China
             

Avactis Biosciences Inc.

("Avactis")

 

Nevada

July 18, 2018

  100% held by AVCO   Integrate and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers
             
International Exosome Association LLC  

Delaware

June 13, 2019

  100% held by AVCO   Provides development services for hospitals and other customers and sells developed items in USA